NDA 021602 · Takeda Pharms USA
Velcade
Bortezomib · Intravenous, Subcutaneous · Proteasome Inhibitor
NovelAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 4, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
May 13, 2003
Approved uses
13
Original approval plus efficacy supplements
Registered trials
1,027
156 Phase 3, 82 recruiting
FAERS reports
89,988
75,667 serious, 14,182 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2025.
VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma VELCADE is indicated for the treatment of adult patients with mantle cell lymphoma.
Mechanism: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic mechanisms can lead to cell death. Experiments have...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 25, 2019 Supplement 44 · Efficacy LetterLabel
- Sep 14, 2015 Supplement 42 · Efficacy · priority review OrphanLabelPediatric Written RequestPediatric Amendment 1
- Oct 8, 2014 Supplement 40 · Efficacy · priority review OrphanLabelLetter
- Aug 8, 2014 Supplement 38 · Efficacy OrphanLetterLabel
- Jan 23, 2012 Supplement 27 · Efficacy LabelReviewLetter
- Nov 1, 2011 Supplement 30 · Efficacy OrphanLabelLetter
- Dec 30, 2009 Supplement 20 · Efficacy · priority review LetterLabel
- Dec 30, 2009 Supplement 19 · Efficacy LabelLetter
- Jun 20, 2008 Supplement 15 · Efficacy · priority review LabelLetterReview
- Oct 10, 2007 Supplement 13 · Efficacy LetterLabel
- Dec 8, 2006 Supplement 10 · Efficacy · priority review LetterLabelReview
- Mar 25, 2005 Supplement 6 · Efficacy · priority review LetterLabel
- May 13, 2003 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelReviewOther Important Information from FDA
1 products under this application
- VELCADE · BORTEZOMIB 3.5MG/VIAL · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Bortezomib" as an intervention, any sponsor and status, largest first.
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT01554852 · 4,420 participants · Start May 2010 · Primary completion Dec 2021
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen; Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen and 7 more · For: Multiple Myeloma
Sites: United Kingdom, United Kingdom
- Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)Pivotal-lookingStatus unknown
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyAcademic, hospital or other
NCT03390387 · 4,000 participants (planned) · Start Nov 2015 · Primary completion Nov 2020
Drug: Dexamethasone continuous; Dexamethasone intermittent and 8 more · For: Childhood Acute Lymphoblastic Leukemia
Sites: Yerevan, Armenia; Homyel, Belarus; Minsk, Belarus · 58 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Pivotal-lookingNot yet recruiting
Children's Oncology GroupResearch network
NCT07072585 · 1,708 participants (planned) · Start Aug 28, 2026 · Primary completion Sep 1, 2035
Drug: Bortezomib; Calaspargase Pegol and 16 more · For: Stage II T Lymphoblastic Leukemia/Lymphoma; Stage III T Lymphoblastic Leukemia/Lymphoma; Stage IV T Lymphoblastic Leukemia/Lymphoma and 2 more
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01371981 · 1,645 participants · Start Jul 6, 2011 · Primary completion Mar 31, 2019
Drug: Asparaginase; Bortezomib and 5 more · For: Acute Myeloid Leukemia; Leukemia Cutis; Myeloid Neoplasm and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 220 sites in all
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaPivotal-lookingCompleted
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT01208766 · 1,503 participants · Start Jan 2011 · Primary completion Dec 2020
Drug: Bortezomib, Melphalan, Prednisone (VMP); 1 or 2 cycle(s) HDM (High Dose Melphalan) and 1 more · For: Multiple Myeloma
Sites: Brisbane, Australia; Canberra, Australia; Melbourne, Australia · 208 sites in all
Wei ZhaoAcademic, hospital or other
NCT03844360 · 1,500 participants (planned) · Start Jan 31, 2016 · Primary completion Dec 31, 2025
Drug: Bortezomib; Eltrombopag and 5 more · For: Hematological Neoplasms
Sites: Xuzhou, China; Tanjin, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- plasma cell myeloma9,241
- neuropathy peripheral6,529
- off label use6,498
- diarrhoea5,237
- fatigue4,581
- death4,220
- pneumonia4,108
- drug ineffective3,816
- thrombocytopenia3,761
- nausea3,129
- pyrexia2,898
- neutropenia2,749
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 486 |
| 2005 | 906 |
| 2006 | 949 |
| 2007 | 930 |
| 2008 | 1,285 |
| 2009 | 1,463 |
| 2010 | 1,604 |
| 2011 | 2,045 |
| 2012 | 3,007 |
| 2013 | 2,560 |
| 2014 | 2,551 |
| 2015 | 8,052 |
| 2016 | 4,697 |
| 2017 | 4,756 |
| 2018 | 5,415 |
| 2019 | 6,400 |
| 2020 | 7,052 |
| 2021 | 7,529 |
| 2022 | 7,188 |
| 2023 | 6,712 |
| 2024 | 5,857 |
| 2025 | 4,910 |
| 2026 | 3,634 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Velcade (Bortezomib)
2024 spending
$670K
Beneficiaries
36
175 claims
Per beneficiary
$18,609
$1,515.66 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,973,142 |
| 2021 | $12,145,291 |
| 2022 | $7,664,156 |
| 2023 | $1,878,202 |
| 2024 | $669,923 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Hungria V, Robak P, Hus M, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, et al. · Nat Med 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Hungria V, Robak P, Hus M, et al. · Lancet Oncol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, et al. · N Engl J Med 2016 · Clinical Trial, Phase III, Multicenter Study
- Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM, Kaufman JL, Laubach J, et al. · Blood 2020 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.